[Ip-health] IP-Watch: Reports: Obama’s Proposed 2014 Budget Favours Patent Office, R&D, Generic Drugs

Thirukumaran Balasubramaniam thiru at keionline.org
Sat Apr 13 02:33:40 PDT 2013


Reports: Obama’s Proposed 2014 Budget Favours Patent Office, R&D, Generic Drugs

http://www.ip-watch.org/2013/04/11/reports-obamas-proposed-2014-budget-favours-patent-office-generic-drugs/

<SNIP>

One news report said that the proposed budget would: ban “pay-to-delay” agreements that delay generic drugs’ entry onto the market; reduce the period of exclusivity for biologics from 12 years to 7 years, as well as prevent evergreening of biologics; and refine the definition of branded drugs while excluding generic drugs from certain calculations on branded drugs. In addition, the budget would promote generic medicines for low-income beneficiaries through differences in co-payments. The total savings from these measures was calculated at some $30 billion.

Another news report said the budget would give benefits to small biotech companies, would institutionalise an R&D tax credit, and increase funds to the Food and Drug Administration (though with a $15 million decrease in budget authority for its drug, biologics and medical device programs).


-- 

Thiru Balasubramaniam
Geneva Representative
Knowledge Ecology International (KEI)

thiru at keionline.org



Tel: +41 22 791 6727
Mobile: +41 76 508 0997










More information about the Ip-health mailing list